{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,30]],"date-time":"2026-10-30T22:31:10Z","timestamp":1793399470299,"version":"4.5.0"},"reference-count":64,"publisher":"Springer Science and Business Media LLC","issue":"11","license":[{"start":{"date-parts":[[2026,6,27]],"date-time":"2026-06-27T00:00:00Z","timestamp":1782518400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2026,6,27]],"date-time":"2026-06-27T00:00:00Z","timestamp":1782518400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"name":"Universit\u00e0 degli Studi dell\u2019Aquila","id":[{"id":"https:\/\/ror.org\/01j9p1r26","id-type":"ROR","asserted-by":"crossref"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["J Endocrinol Invest"],"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>The cardiovascular safety of testosterone replacement therapy (TRT) in older men with hypogonadism has been debated for over a decade, largely on the basis of underpowered trials and conflicting observational data. The TRAVERSE trial, published in 2023, provided the first adequately powered, placebo-controlled evidence on this question.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Objectives<\/jats:title>\n                    <jats:p>This review synthesises current evidence on the cardiovascular safety of TRT in older men, with particular attention to the interpretation of TRAVERSE findings, the clinical significance of non-MACE safety signals, and the practical management of organic versus functional hypogonadism.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>A systematic search of PubMed\/MEDLINE, Embase, and the Cochrane Central Register of Controlled Trials (CENTRAL) was conducted through March 2026. Approximately 450 articles were identified; 64 met the inclusion criteria and were selected for review. Evidence was appraised according to study design, with RCTs and meta-analyses weighted above observational data.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>\n                      TRAVERSE demonstrated non-inferiority of TRT versus placebo for major adverse cardiovascular events (MACE) in men with confirmed hypogonadism and elevated cardiovascular risk (HR 0.96, 95% CI 0.78\u20131.17) [5]. Non-MACE signals \u2014 including atrial fibrillation (3.1% vs. 2.4%), pulmonary embolism (2.0% vs. 1.5%), and acute kidney injury (2.3% vs. 1.5%) \u2014 were numerically higher in the TRT arm but did not reach statistical significance within the trial. In contrast, large observational cohorts consistently report statistically significant associations between TRT and AF and VTE. Erythrocytosis was the most reproducible adverse effect (17.0% vs. 3.3%,\n                      <jats:italic>p<\/jats:italic>\n                      \u2009&lt;\u20090.001). Functional hypogonadism secondary to obesity or metabolic syndrome responds to lifestyle intervention and GLP-1\/GIP agonists, with testosterone normalisation in 81.4% at 6 months and 89.5% at 24 months after bariatric surgery [45].\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions<\/jats:title>\n                    <jats:p>TRT does not increase MACE risk in men with confirmed organic hypogonadism when titrated to physiological levels. Non-MACE signals warrant vigilance rather than contraindication. Metabolic optimisation should precede TRT in functional hypogonadism. Individualised monitoring and careful patient selection remain essential.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1007\/s40618-026-02945-w","type":"journal-article","created":{"date-parts":[[2026,6,27]],"date-time":"2026-06-27T05:53:42Z","timestamp":1782539622000},"page":"3223-3242","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":2,"title":["Testosterone replacement therapy and cardiovascular safety in older men: lessons from TRAVERSE and beyond"],"prefix":"10.1007","volume":"49","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-9359-7955","authenticated-orcid":false,"given":"Daniele","family":"Tienforti","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Giovanni","family":"Terrana","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Riccardo","family":"Di Geronimo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Elisabetta","family":"Perfetto","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Luca","family":"Spagnolo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marco Giorgio","family":"Baroni","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Arcangelo","family":"Barbonetti","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,6,27]]},"reference":[{"issue":"2","key":"2945_CR1","doi-asserted-by":"publisher","first-page":"109","DOI":"10.1056\/NEJMoa1000485","volume":"363","author":"S Basaria","year":"2010","unstructured":"Basaria S, Coviello AD, Travison TG, Storer TW, Farwell WR, Jette AM, Eder R, Tennstedt S, Ulloor J, Zhang A, Choong K, Lakshman KM, Mazer NA, Miciek R, Krasnoff J, Elmi A, Knapp PE, Brooks B, Appleman E, Aggarwal S, Bhasin G, Hede-Brierley L, Bhatia A, Collins L, LeBrasseur N, Fiore LD, Bhasin S (2010) Adverse events associated with testosterone administration. N Engl J Med 363(2):109\u2013122. https:\/\/doi.org\/10.1056\/NEJMoa1000485","journal-title":"N Engl J Med"},{"issue":"17","key":"2945_CR2","doi-asserted-by":"publisher","first-page":"1829","DOI":"10.1001\/jama.2013.280386","volume":"310","author":"R Vigen","year":"2013","unstructured":"Vigen R, O\u2019Donnell CI, Bar\u00f3n AE et al (2013) Association of testosterone therapy with mortality, myocardial infarction, and stroke. JAMA 310(17):1829\u20131836. https:\/\/doi.org\/10.1001\/jama.2013.280386","journal-title":"JAMA"},{"issue":"1","key":"2945_CR3","doi-asserted-by":"publisher","first-page":"e85805","DOI":"10.1371\/journal.pone.0085805","volume":"9","author":"WD Finkle","year":"2014","unstructured":"Finkle WD, Greenland S, Ridgeway GK, Adams JL, Frasco MA, Cook MB, Fraumeni JF Jr, Hoover RN (2014) Increased risk of non-fatal myocardial infarction following testosterone therapy prescription in men. PLoS ONE 9(1):e85805. https:\/\/doi.org\/10.1371\/journal.pone.0085805","journal-title":"PLoS ONE"},{"key":"2945_CR4","doi-asserted-by":"publisher","first-page":"108","DOI":"10.1186\/1741-7015-11-108","volume":"11","author":"L Xu","year":"2013","unstructured":"Xu L, Freeman G, Cowling BJ, Schooling CM (2013) Testosterone therapy and cardiovascular events among men: a systematic review and meta-analysis of placebo-controlled randomized trials. BMC Med 11:108. https:\/\/doi.org\/10.1186\/1741-7015-11-108","journal-title":"BMC Med"},{"issue":"2","key":"2945_CR5","doi-asserted-by":"publisher","first-page":"107","DOI":"10.1056\/NEJMoa2215025","volume":"389","author":"AM Lincoff","year":"2023","unstructured":"Lincoff AM, Bhasin S, Flevaris P, Mitchell LM, Basaria S, Boden WE, Cunningham GR, Granger CB, Khera M, Thompson IM Jr, Wang Q, Wolski K, Davey D, Kalahasti V, Khan N, Miller MG, Snabes MC, Chan A, Dubcenco E, Li X, Yi T, Huang B, Pencina KM, Travison TG, Nissen SE (2023) Cardiovascular safety of testosterone-replacement therapy. N Engl J Med 389(2):107\u2013117. https:\/\/doi.org\/10.1056\/NEJMoa2215025","journal-title":"N Engl J Med"},{"key":"2945_CR6","doi-asserted-by":"publisher","first-page":"i5968","DOI":"10.1136\/bmj.i5968","volume":"355","author":"C Martinez","year":"2016","unstructured":"Martinez C, Suissa S, Rietbrock S, Katholing A, Freedman B, Cohen AT, Handelsman DJ (2016) Testosterone treatment and risk of venous thromboembolism: population based case-control study. BMJ 355:i5968. https:\/\/doi.org\/10.1136\/bmj.i5968","journal-title":"BMJ"},{"issue":"2","key":"2945_CR7","doi-asserted-by":"publisher","first-page":"190","DOI":"10.1001\/jamainternmed.2019.5135","volume":"180","author":"RF Walker","year":"2020","unstructured":"Walker RF, Zakai NA, MacLehose RF, Cowan LT, Adam TJ, Alonso A, Lutsey PL (2020) Association of testosterone therapy with risk of venous thromboembolism among men with and without hypogonadism. JAMA Intern Med 180(2):190\u2013197. https:\/\/doi.org\/10.1001\/jamainternmed.2019.5135","journal-title":"JAMA Intern Med"},{"issue":"6","key":"2945_CR8","doi-asserted-by":"publisher","first-page":"e381","DOI":"10.1016\/S2666-7568(22)00096-4","volume":"3","author":"J Hudson","year":"2022","unstructured":"Hudson J, Cruickshank M, Quinton R, Aucott L, Aceves-Martins M, Gillies K, Bhasin S, Snyder PJ, Ellenberg SS, Grossmann M, Travison TG, Gianatti EJ, van der Schouw YT, Emmelot-Vonk MH, Giltay EJ, Hackett G, Ramachandran S, Svartberg J, Hildreth KL, Groti Antonic K, Brock GB, Tenover JL, Tan HM, Kong CHC, Tan WS, Marks LS, Ross RJ, Schwartz RS, Manson P, Roberts S, Andersen MS, Magnussen LV, Hern\u00e1ndez R, Oliver N, Wu F, Dhillo WS, Bhattacharya S, Brazzelli M, Jayasena CN (2022) Adverse cardiovascular events and mortality in men during testosterone treatment: an individual patient and aggregate data meta-analysis. Lancet Healthy Longev 3(6):e381\u2013e393. https:\/\/doi.org\/10.1016\/S2666-7568(22)00096-4","journal-title":"Lancet Healthy Longev"},{"issue":"6","key":"2945_CR9","doi-asserted-by":"publisher","first-page":"964","DOI":"10.1136\/jim-2017-000411","volume":"65","author":"G Corona","year":"2017","unstructured":"Corona G, Dicuio M, Rastrelli G, Maseroli E, Lotti F, Sforza A, Maggi M (2017) Testosterone treatment and cardiovascular and venous thromboembolism risk: what is new? J Investig Med 65(6):964\u2013973. https:\/\/doi.org\/10.1136\/jim-2017-000411","journal-title":"J Investig Med"},{"issue":"2","key":"2945_CR10","doi-asserted-by":"publisher","first-page":"423","DOI":"10.1016\/j.juro.2018.03.115","volume":"200","author":"JP Mulhall","year":"2018","unstructured":"Mulhall JP, Trost LW, Brannigan RE, Kurtz EG, Redmon JB, Chiles KA, Lightner DJ, Miner MM, Murad MH, Nelson CJ, Platz EA, Ramanathan LV, Lewis RW (2018) Evaluation and management of testosterone deficiency: AUA guideline. J Urol 200(2):423\u2013432. https:\/\/doi.org\/10.1016\/j.juro.2018.03.115","journal-title":"J Urol"},{"issue":"12","key":"2945_CR11","doi-asserted-by":"publisher","first-page":"2385","DOI":"10.1007\/s40618-022-01859-7","volume":"45","author":"AM Isidori","year":"2022","unstructured":"Isidori AM, Aversa A, Calogero A, Ferlin A, Francavilla S, Lanfranco F, Pivonello R, Rochira V, Corona G, Maggi M (2022) Adult- and late-onset male hypogonadism: the clinical practice guidelines of the Italian Society of Andrology and Sexual Medicine (SIAMS) and the Italian Society of Endocrinology (SIE). J Endocrinol Invest 45(12):2385\u20132403. https:\/\/doi.org\/10.1007\/s40618-022-01859-7","journal-title":"J Endocrinol Invest"},{"key":"2945_CR12","doi-asserted-by":"publisher","first-page":"1496906","DOI":"10.3389\/fendo.2024.1496906","volume":"15","author":"A Neidhart","year":"2025","unstructured":"Neidhart A, von Wyl V, K\u00e4slin B, Henzen C, Fischli S (2025) Prevalence and predictive factors of testosterone-induced erythrocytosis: a retrospective single center study. Front Endocrinol (Lausanne) 15:1496906. https:\/\/doi.org\/10.3389\/fendo.2024.1496906","journal-title":"Front Endocrinol (Lausanne)"},{"key":"2945_CR13","doi-asserted-by":"publisher","first-page":"25","DOI":"10.1080\/14656566.2024.2306832","volume":"25","author":"PM Luther","year":"2024","unstructured":"Luther PM, Spillers NJ, Talbot NC, Sinnathamby ES, Ellison D, Kelkar RA, Ahmadzadeh S, Shekoohi S, Kaye AD (2024) Testosterone replacement therapy: clinical considerations. Expert Opin Pharmacother 25:25\u201335. https:\/\/doi.org\/10.1080\/14656566.2024.2306832","journal-title":"Expert Opin Pharmacother"},{"key":"2945_CR14","doi-asserted-by":"crossref","unstructured":"Basheer B, Ila V, Barros R, Mesquita F, Lopes LS, Lima VFN, Favorito LA, Ramasamy R (2025) Management of Adverse Effects in Testosterone Replacement Therapy. Int Braz J Urol 51(3):e20259904","DOI":"10.1590\/s1677-5538.ibju.2025.9904"},{"key":"2945_CR15","doi-asserted-by":"publisher","first-page":"e70064","DOI":"10.1002\/edm2.70064","volume":"8","author":"M Kabha","year":"2025","unstructured":"Kabha M, Dana H, Kassem S, Dekel Y, Cohen H, Zaina A (2025) Secondary erythrocytosis among type 2 diabetes mellitus patients with hypogonadism using sodium-glucose cotransporter 2 inhibitors and testosterone replacement therapy. Endocrinol Diabetes Metab 8:e70064. https:\/\/doi.org\/10.1002\/edm2.70064","journal-title":"Endocrinol Diabetes Metab"},{"issue":"1","key":"2945_CR16","doi-asserted-by":"publisher","first-page":"51","DOI":"10.1016\/j.eprac.2023.09.012","volume":"30","author":"A Sood","year":"2024","unstructured":"Sood A, Hosseinpour A, Sood A, Avula S, Durrani J, Bhatia V et al (2024) Cardiovascular Outcomes of Hypogonadal Men Receiving Testosterone Replacement Therapy: A Meta-analysis of Randomized Controlled Trials. Endocr Pract 30(1):51\u201361. https:\/\/doi.org\/10.1016\/j.eprac.2023.09.012","journal-title":"Endocr Pract"},{"key":"2945_CR17","doi-asserted-by":"publisher","first-page":"893","DOI":"10.1097\/HJH.0000000000003638","volume":"42","author":"TB Olesen","year":"2024","unstructured":"Olesen TB, Glintborg D, J\u00f8hnk F, Olsen MH, Andersen MS (2024) Blood pressure responses to testosterone therapy are amplified by hematocrit levels in opioid-induced androgen deficiency: a double-blind, randomized, placebo-controlled trial. J Hypertens 42:893\u2013901. https:\/\/doi.org\/10.1097\/HJH.0000000000003638","journal-title":"J Hypertens"},{"issue":"Suppl 1","key":"2945_CR18","doi-asserted-by":"publisher","first-page":"S12","DOI":"10.4103\/2230-8210.94248","volume":"16","author":"R Salam","year":"2012","unstructured":"Salam R, Kshetrimayum AS, Keisam R (2012) Testosterone and metabolic syndrome: the link. Indian J Endocrinol Metab 16(Suppl 1):S12\u2013S19. https:\/\/doi.org\/10.4103\/2230-8210.94248","journal-title":"Indian J Endocrinol Metab"},{"key":"2945_CR19","doi-asserted-by":"publisher","first-page":"227","DOI":"10.1111\/cen.14643","volume":"96","author":"A Sharma","year":"2022","unstructured":"Sharma A, Ul-Haq Z, Sindi E, Al-Sharefi A, Kamalati T, Dhillo WS, Minhas S, Jayasena CN (2022) Clinical characteristics and comorbidities associated with testosterone prescribing in men. Clin Endocrinol (Oxf) 96:227\u2013235. https:\/\/doi.org\/10.1111\/cen.14643","journal-title":"Clin Endocrinol (Oxf)"},{"key":"2945_CR20","doi-asserted-by":"publisher","first-page":"qdaf306","DOI":"10.1093\/jsxmed\/qdaf306","volume":"23","author":"DS Bal","year":"2026","unstructured":"Bal DS, Fidel MG, Panchendrabose K, Mann U, Brar R, Patel P (2026) Association between testosterone replacement therapy and cardiovascular events in men: a retrospective propensity-weighted analysis. J Sex Med 23:qdaf306. https:\/\/doi.org\/10.1093\/jsxmed\/qdaf306","journal-title":"J Sex Med"},{"key":"2945_CR21","doi-asserted-by":"publisher","first-page":"e745","DOI":"10.1210\/clinem\/dgad526","volume":"109","author":"B Xu","year":"2024","unstructured":"Xu B, Mo W, Tan X, Zhang P, Huang J, Huang C, Guo D, Wei X, Liu Y, Lei X, Dou W, Lin J, Liu D, Yang L, Huang Y, Zhang H, Liao Y (2024) Associations of serum testosterone and sex hormone-binding globulin with incident arrhythmias in men from UK Biobank. J Clin Endocrinol Metab 109:e745\u2013e756. https:\/\/doi.org\/10.1210\/clinem\/dgad526","journal-title":"J Clin Endocrinol Metab"},{"key":"2945_CR22","doi-asserted-by":"publisher","first-page":"1182113","DOI":"10.3389\/fphar.2023.1182113","volume":"14","author":"H Zhao","year":"2023","unstructured":"Zhao H, Li JM, Li ZR, Zhang Q, Zhong MK, Yan MM, Qiu XY (2023) Major adverse cardiovascular events associated with testosterone treatment: a pharmacovigilance study of the FAERS database. Front Pharmacol https:\/\/doi.org\/10.3389\/fphar.2023.1182113","journal-title":"Front Pharmacol"},{"issue":"5","key":"2945_CR23","doi-asserted-by":"publisher","first-page":"467","DOI":"10.1016\/j.ceca.2006.09.003","volume":"41","author":"F Er","year":"2007","unstructured":"Er F, Michels G, Brandt MC, Khan IF, Haase H, Eicks M et al (2007) Impact of testosterone on cardiac L-type calcium channels and Ca2\u2009+\u2009sparks: acute actions antagonize chronic effects. Cell Calcium 41(5):467\u2013477. https:\/\/doi.org\/10.1016\/j.ceca.2006.09.003","journal-title":"Cell Calcium"},{"issue":"13","key":"2945_CR24","doi-asserted-by":"publisher","first-page":"1666","DOI":"10.1161\/01.CIR.99.13.1666","volume":"99","author":"GMC Rosano","year":"1999","unstructured":"Rosano GMC, Leonardo F, Pagnotta P, Pelliccia F, Panina G, Cerquetani E et al (1999) Acute anti-ischemic effect of testosterone in men with coronary artery disease. Circulation 99(13):1666\u20131670. https:\/\/doi.org\/10.1161\/01.CIR.99.13.1666","journal-title":"Circulation"},{"key":"2945_CR25","doi-asserted-by":"publisher","DOI":"10.33963\/v.phj.111620","author":"L Szarpak","year":"2026","unstructured":"Szarpak L, Maslyk M, Kaminska H, Al-Jeabory M, Pruc M, Denegri A (2026) Testosterone replacement therapy and non-major adverse cardiovascular events safety signals: atrial fibrillation, acute kidney injury, and pulmonary embolism. Kardiol Pol. https:\/\/doi.org\/10.33963\/v.phj.111620","journal-title":"Kardiol Pol"},{"key":"2945_CR26","doi-asserted-by":"publisher","first-page":"144","DOI":"10.4103\/aja202352","volume":"26","author":"R Cannarella","year":"2024","unstructured":"Cannarella R, Gusmano C, Leanza C, Garofalo V, Crafa A, Barbagallo F, Condorelli RA, Vignera S, Calogero AE (2024) Testosterone replacement therapy and vascular thromboembolic events: a systematic review and meta-analysis. Asian J Androl 26:144\u2013154. https:\/\/doi.org\/10.4103\/aja202352","journal-title":"Asian J Androl"},{"key":"2945_CR27","doi-asserted-by":"publisher","first-page":"e63611","DOI":"10.7759\/cureus.63611","volume":"16","author":"K Bragg","year":"2024","unstructured":"Bragg K, Miller H, Buckshaw R, Simon LV, King C (2024) Testosterone therapy as an isolated risk factor for venous thrombosis: a case report. Cureus 16:e63611. https:\/\/doi.org\/10.7759\/cureus.63611","journal-title":"Cureus"},{"key":"2945_CR28","doi-asserted-by":"publisher","first-page":"1201","DOI":"10.1093\/jsxmed\/qdae138","volume":"21","author":"DR Greenberg","year":"2024","unstructured":"Greenberg DR, Kohn TP, Asanad K, Brannigan RE, Halpern JA (2024) Association of testosterone replacement therapy with atrial fibrillation and acute kidney injury. J Sex Med 21:1201\u20131203. https:\/\/doi.org\/10.1093\/jsxmed\/qdae138","journal-title":"J Sex Med"},{"key":"2945_CR29","doi-asserted-by":"publisher","DOI":"10.1016\/j.arth.2026.01.027","author":"AM Omurzakov","year":"2026","unstructured":"Omurzakov AM, Omurzakov A, Bhatti P, Debbi EM, Gausden EB, Chalmers BP (2026) Preoperative testosterone replacement therapy is associated with increased complication risk after total hip arthroplasty: a propensity-matched analysis of real-world data. J Arthroplasty. https:\/\/doi.org\/10.1016\/j.arth.2026.01.027","journal-title":"J Arthroplasty"},{"key":"2945_CR30","doi-asserted-by":"publisher","DOI":"10.1016\/j.arth.2025.10.066","author":"A Omurzakov","year":"2025","unstructured":"Omurzakov A, Omurzakov AM, Bhatti P, Debbi EM, Gausden EB, Chalmers BP (2025) Preoperative testosterone replacement therapy is associated with increased complication risk after total knee arthroplasty: a propensity-matched analysis of 13,250 patients. J Arthroplasty. https:\/\/doi.org\/10.1016\/j.arth.2025.10.066","journal-title":"J Arthroplasty"},{"key":"2945_CR31","doi-asserted-by":"publisher","first-page":"689","DOI":"10.1016\/j.jse.2025.07.022","volume":"35","author":"AE White","year":"2026","unstructured":"White AE, Omurzakov A, Omurzakov AM, Athanasian CE, Brusalis CM, Kew ME, Fu MC, Gulotta LV, Taylor SA (2026) Preoperative testosterone replacement therapy is associated with increased rates of periprosthetic joint infection, acute kidney injury, and emergency department utilization after total shoulder arthroplasty: a propensity-score matched analysis. J Shoulder Elb Surg 35:689\u2013696. https:\/\/doi.org\/10.1016\/j.jse.2025.07.022","journal-title":"J Shoulder Elb Surg"},{"key":"2945_CR32","doi-asserted-by":"publisher","DOI":"10.1016\/j.jse.2025.12.013","author":"J Lawand","year":"2026","unstructured":"Lawand J, Mirahmadi A, Holle AM, Parmar RP, Elias T, Somerson J, Hill B, Khan A, Horneff J, Abboud J (2026) Association of preoperative testosterone replacement therapy with postoperative complications following rotator cuff repair. J Shoulder Elb Surg. https:\/\/doi.org\/10.1016\/j.jse.2025.12.013","journal-title":"J Shoulder Elb Surg"},{"key":"2945_CR33","doi-asserted-by":"publisher","first-page":"1341","DOI":"10.1002\/jso.27638","volume":"129","author":"DR Greenberg","year":"2024","unstructured":"Greenberg DR, Rhodes SP, Lazarovich A, Bhambhvani HP, Gago LC, Patel HD, Brannigan RE, Shoag JE, Halpern JA (2024) Hypogonadism, frailty, and postoperative outcomes among men undergoing radical nephrectomy. J Surg Oncol 129:1341\u20131347. https:\/\/doi.org\/10.1002\/jso.27638","journal-title":"J Surg Oncol"},{"key":"2945_CR34","doi-asserted-by":"publisher","first-page":"378","DOI":"10.1186\/s12933-025-02930-2","volume":"24","author":"F Bonnet","year":"2025","unstructured":"Bonnet F, Vaduva P, Halimi JM, Dosda A, Ducluzeau PH, Koppe L, Fauchier L (2025) Testosterone therapy is associated with reduced risk of acute kidney injury, kidney failure with renal replacement therapy, and cardiovascular events in men with diabetes and hypogonadism. Cardiovasc Diabetol 24:378. https:\/\/doi.org\/10.1186\/s12933-025-02930-2","journal-title":"Cardiovasc Diabetol"},{"key":"2945_CR35","doi-asserted-by":"publisher","first-page":"108961","DOI":"10.1016\/j.maturitas.2026.108961","volume":"209","author":"P Anagnostis","year":"2026","unstructured":"Anagnostis P, Divaris E, Zidrou M, Kassi E, Tournis S (2026) Effect of testosterone replacement therapy on fracture risk in hypogonadal men: a systematic review and meta-analysis of randomized controlled trials. Maturitas 209:108961. https:\/\/doi.org\/10.1016\/j.maturitas.2026.108961","journal-title":"Maturitas"},{"key":"2945_CR36","doi-asserted-by":"publisher","first-page":"e24","DOI":"10.5435\/JAAOSGlobal-D-24-00248","volume":"9","author":"M Singh","year":"2025","unstructured":"Singh M, Daher M, Diebo BG, Daniels AH, Arcand MA (2025) Testosterone Replacement Therapy Is Associated With Increased Incidence Rate of Vertebral Fractures: A Matched Retrospective Analysis. JAAOS Glob Res Rev 9:e24. https:\/\/doi.org\/10.5435\/JAAOSGlobal-D-24-00248","journal-title":"JAAOS Glob Res Rev"},{"key":"2945_CR37","doi-asserted-by":"publisher","first-page":"100631","DOI":"10.1016\/j.xrrt.2025.100631","volume":"6","author":"PH Arcand","year":"2026","unstructured":"Arcand PH, Peresuh SJ, Confessore J, Testa EJ, Quinn M, Singh M et al (2026) The relationship between testosterone replacement therapy and incidence of proximal humerus fractures in men: a matched retrospective analysis. JSES Rev Rep Tech 6:100631. https:\/\/doi.org\/10.1016\/j.xrrt.2025.100631","journal-title":"JSES Rev Rep Tech"},{"key":"2945_CR38","doi-asserted-by":"publisher","first-page":"203","DOI":"10.1056\/NEJMoa2308836","volume":"390","author":"PJ Snyder","year":"2024","unstructured":"Snyder PJ, Bauer DC, Ellenberg SS, Cauley JA, Buhr KA, Bhasin S, Miller MG, Khan NS, Li X, Nissen SE (2024) Testosterone treatment and fractures in men with hypogonadism. N Engl J Med 390:203\u2013211. https:\/\/doi.org\/10.1056\/NEJMoa2308836","journal-title":"N Engl J Med"},{"key":"2945_CR39","doi-asserted-by":"publisher","first-page":"471","DOI":"10.1001\/jamainternmed.2016.9539","volume":"177","author":"PJ Snyder","year":"2017","unstructured":"Snyder PJ, Kopperdahl DL, Stephens-Shields AJ, Ellenberg SS, Cauley JA, Ensrud KE, Lewis CE, Barrett-Connor E, Schwartz AV, Lee DC, Bhasin S, Cunningham GR, Gill TM, Matsumoto AM, Swerdloff RS, Basaria S, Diem SJ, Wang C, Hou X, Cifelli D, Dougar D, Zeldow B, Bauer DC, Keaveny TM (2017) Effect of testosterone treatment on volumetric bone density and strength in older men with low testosterone: a controlled clinical trial. JAMA Intern Med 177:471\u2013479. https:\/\/doi.org\/10.1001\/jamainternmed.2016.9539","journal-title":"JAMA Intern Med"},{"key":"2945_CR40","doi-asserted-by":"publisher","first-page":"e3143","DOI":"10.1210\/clinem\/dgab149","volume":"106","author":"M Ng Tang Fui","year":"2021","unstructured":"Ng Tang Fui M, Hoermann R, Bracken K, Handelsman DJ, Inder WJ, Stuckey BGA, Yeap BB, Ghasem-Zadeh A, Robledo KP, Jesudason D, Zajac JD, Wittert GA, Grossmann M (2021) Effect of testosterone treatment on bone microarchitecture and bone mineral density in men: a 2-year randomized controlled trial. J Clin Endocrinol Metab 106:e3143\u2013e3158. https:\/\/doi.org\/10.1210\/clinem\/dgab149","journal-title":"J Clin Endocrinol Metab"},{"key":"2945_CR41","doi-asserted-by":"publisher","first-page":"530","DOI":"10.3390\/jcm10030530","volume":"10","author":"K Shigehara","year":"2021","unstructured":"Shigehara K, Izumi K, Kadono Y, Mizokami A (2021) Testosterone and bone health in men: a narrative review. J Clin Med 10:530. https:\/\/doi.org\/10.3390\/jcm10030530","journal-title":"J Clin Med"},{"key":"2945_CR42","doi-asserted-by":"publisher","first-page":"1715","DOI":"10.1210\/jc.2018-00229","volume":"103","author":"S Bhasin","year":"2018","unstructured":"Bhasin S, Brito JP, Cunningham GR, Hayes FJ, Hodis HN, Matsumoto AM, Snyder PJ, Swerdloff RS, Wu FC, Yialamas MA (2018) Testosterone therapy in men with hypogonadism: an Endocrine Society clinical practice guideline. J Clin Endocrinol Metab 103:1715\u20131744. https:\/\/doi.org\/10.1210\/jc.2018-00229","journal-title":"J Clin Endocrinol Metab"},{"issue":"3","key":"2945_CR43","doi-asserted-by":"publisher","first-page":"369","DOI":"10.1210\/er.2017-00234","volume":"39","author":"PJ Snyder","year":"2018","unstructured":"Snyder PJ, Bhasin S, Cunningham GR et al (2018) Lessons from the testosterone trials. Endocr Rev 39(3):369\u2013386. https:\/\/doi.org\/10.1210\/er.2017-00234","journal-title":"Endocr Rev"},{"issue":"1","key":"2945_CR44","doi-asserted-by":"publisher","first-page":"92","DOI":"10.1186\/s12958-025-01425-9","volume":"23","author":"S La Vignera","year":"2025","unstructured":"La Vignera S, Cannarella R, Garofalo V, Crafa A, Barbagallo F, Condorelli RA, Calogero AE (2025) Short-term impact of tirzepatide on metabolic hypogonadism and body composition in patients with obesity: a controlled pilot study. Reprod Biol Endocrinol 23(1):92. https:\/\/doi.org\/10.1186\/s12958-025-01425-9","journal-title":"Reprod Biol Endocrinol"},{"issue":"12","key":"2945_CR45","doi-asserted-by":"publisher","first-page":"1835","DOI":"10.1007\/s11695-012-0734-9","volume":"22","author":"S Pellitero","year":"2012","unstructured":"Pellitero S, Olaizola I, Alastrue A et al (2012) Hypogonadotropic hypogonadism in morbidly obese males is reversed after bariatric surgery. Obes Surg 22(12):1835\u20131842. https:\/\/doi.org\/10.1007\/s11695-012-0734-9","journal-title":"Obes Surg"},{"issue":"3","key":"2945_CR46","doi-asserted-by":"publisher","first-page":"195","DOI":"10.1530\/EC-18-0514","volume":"8","author":"M Jensterle","year":"2019","unstructured":"Jensterle M, Podbregar A, Goricar K, Gregoric N, Janez A (2019) Effects of liraglutide on obesity-associated functional hypogonadism in men. Endocr Connect 8(3):195\u2013202. https:\/\/doi.org\/10.1530\/EC-18-0514","journal-title":"Endocr Connect"},{"issue":"3","key":"2945_CR47","doi-asserted-by":"publisher","first-page":"e814","DOI":"10.1210\/clinem\/dgae249","volume":"110","author":"AM Gonzalez-Gil","year":"2025","unstructured":"Gonzalez-Gil AM, Barnouin Y, Celli A, Viola V, Villarreal MD, Nava D, Sciuk ML, Qualls A, Armamento-Villareal C, R., Villareal DT (2025) Metabolic Effects of Testosterone Added to Intensive Lifestyle Intervention in Older Men With Obesity and Hypogonadism. J Clin Endocrinol Metab 110(3):e814\u2013e826. https:\/\/doi.org\/10.1210\/clinem\/dgae249","journal-title":"J Clin Endocrinol Metab"},{"issue":"2","key":"2945_CR48","doi-asserted-by":"publisher","first-page":"519","DOI":"10.1111\/dom.16042","volume":"27","author":"N Gregori\u010d","year":"2025","unstructured":"Gregori\u010d N, \u0160ikonja J, Jane\u017e A, Jensterle M (2025) Semaglutide improved sperm morphology in obese men with type 2 diabetes mellitus and functional hypogonadism. Diabetes Obes Metab 27(2):519\u2013528. https:\/\/doi.org\/10.1111\/dom.16042","journal-title":"Diabetes Obes Metab"},{"issue":"2","key":"2945_CR49","doi-asserted-by":"publisher","first-page":"163","DOI":"10.1080\/17446651.2023.2296022","volume":"19","author":"G Corona","year":"2024","unstructured":"Corona G, Rastrelli G, Sparano C, Vignozzi L, Sforza A, Maggi M (2024) Advances in the treatment of functional male hypogonadism. Expert Rev Endocrinol metabolism 19(2):163\u2013177. https:\/\/doi.org\/10.1080\/17446651.2023.2296022","journal-title":"Expert Rev Endocrinol metabolism"},{"issue":"2","key":"2945_CR50","doi-asserted-by":"publisher","first-page":"93689","DOI":"10.5493\/wjem.v14.i2.93689","volume":"14","author":"MT Shenoy","year":"2024","unstructured":"Shenoy MT, Mondal S, Fernandez CJ, Pappachan JM (2024) Management of male obesity-related secondary hypogonadism: A clinical update. World J experimental Med 14(2):93689. https:\/\/doi.org\/10.5493\/wjem.v14.i2.93689","journal-title":"World J experimental Med"},{"issue":"4","key":"2945_CR51","doi-asserted-by":"publisher","first-page":"241","DOI":"10.1080\/13685538.2018.1506918","volume":"22","author":"I Khripun","year":"2019","unstructured":"Khripun I, Vorobyev S, Belousov I, Kogan M, Zitzmann M (2019) Influence of testosterone substitution on glycemic control and endothelial markers in men with newly diagnosed functional hypogonadism and type 2 diabetes mellitus: a randomized controlled trial. aging male: official J Int Soc Study Aging Male 22(4):241\u2013249. https:\/\/doi.org\/10.1080\/13685538.2018.1506918","journal-title":"aging male: official J Int Soc Study Aging Male"},{"issue":"3","key":"2945_CR52","doi-asserted-by":"publisher","first-page":"277","DOI":"10.1080\/14740338.2018.1424831","volume":"17","author":"G Corona","year":"2018","unstructured":"Corona G, Rastrelli G, Reisman Y, Sforza A, Maggi M (2018) The safety of available treatments of male hypogonadism in organic and functional hypogonadism. Expert Opin Drug Saf 17(3):277\u2013292. https:\/\/doi.org\/10.1080\/14740338.2018.1424831","journal-title":"Expert Opin Drug Saf"},{"issue":"5","key":"2945_CR53","doi-asserted-by":"publisher","first-page":"970","DOI":"10.1111\/andr.12770","volume":"8","author":"G Corona","year":"2020","unstructured":"Corona G, Goulis DG, Huhtaniemi I, Zitzmann M, Toppari J, Forti G, Vanderschueren D, Wu FC (2020) European Academy of Andrology (EAA) guidelines on investigation, treatment and monitoring of functional hypogonadism in males: Endorsing organization: European Society of Endocrinology. Andrology 8(5):970\u2013987. https:\/\/doi.org\/10.1111\/andr.12770","journal-title":"Andrology"},{"issue":"1","key":"2945_CR54","doi-asserted-by":"publisher","first-page":"21","DOI":"10.3390\/ijms22010021","volume":"22","author":"V Ide","year":"2021","unstructured":"Ide V, Vanderschueren D, Antonio L (2021) Trattamento degli uomini con ipogonadismo centrale: alternative alla terapia sostitutiva con testosterone. Int J Mol Sci 22(1):21. https:\/\/doi.org\/10.3390\/ijms22010021","journal-title":"Int J Mol Sci"},{"issue":"6","key":"2945_CR55","doi-asserted-by":"publisher","first-page":"1590","DOI":"10.1111\/andr.12725","volume":"8","author":"M Awouters","year":"2020","unstructured":"Awouters M, Vanderschueren D, Antonio L (2020) Aromatase inhibitors and selective estrogen receptor modulators: Unconventional therapies for functional hypogonadism? Andrology 8(6):1590\u20131597. https:\/\/doi.org\/10.1111\/andr.12725","journal-title":"Andrology"},{"key":"2945_CR56","doi-asserted-by":"publisher","first-page":"1198437","DOI":"10.3389\/fendo.2023.1198437","volume":"14","author":"R Indirli","year":"2023","unstructured":"Indirli R, Lanzi V, Arosio M, Mantovani G, Ferrante E (2023) The association of hypogonadism with depression and its treatments. Front Endocrinol (Lausanne) 14:1198437. https:\/\/doi.org\/10.3389\/fendo.2023.1198437","journal-title":"Front Endocrinol (Lausanne)"},{"issue":"4","key":"2945_CR57","doi-asserted-by":"publisher","first-page":"7","DOI":"10.1016\/j.beem.2022.101626","volume":"36","author":"CW Friederick","year":"2022","unstructured":"Friederick CW (2022) Wu. Ageing male (part 2): Management of functional hypogonadism in older men, a patient-centric holistic approach. Best Pract Res Clin Endocrinol Metab 36(4):7. https:\/\/doi.org\/10.1016\/j.beem.2022.101626","journal-title":"Best Pract Res Clin Endocrinol Metab"},{"issue":"3","key":"2945_CR58","doi-asserted-by":"publisher","first-page":"679","DOI":"10.1007\/s42000-025-00658-y","volume":"24","author":"N Theodorakis","year":"2025","unstructured":"Theodorakis N, Kreouzi M, Hitas C, Anagnostou D, Kollia Z, Vamvakou G, Nikolaou M (2025) Testosterone replacement therapy in heart failure: A systematic review of randomized controlled trials. Horm (Athens) 24(3):679\u2013693. https:\/\/doi.org\/10.1007\/s42000-025-00658-y","journal-title":"Horm (Athens)"},{"issue":"12","key":"2945_CR59","doi-asserted-by":"publisher","first-page":"1787","DOI":"10.1016\/j.jsxm.2016.10.009","volume":"13","author":"M Khera","year":"2016","unstructured":"Khera M, Adaikan G, Buvat J, Carrier S, El-Meliegy A, Hatzimouratidis K, McCullough A, Morgentaler A, Torres LO, Salonia A (2016) Diagnosis and Treatment of Testosterone Deficiency: Recommendations From the Fourth International Consultation for Sexual Medicine (ICSM 2015). J Sex Med 13(12):1787\u20131804. https:\/\/doi.org\/10.1016\/j.jsxm.2016.10.009","journal-title":"J Sex Med"},{"key":"2945_CR60","doi-asserted-by":"publisher","unstructured":"Braga MAP, Rivera A, Marinheiro G, Felix N, Carvalho PEP, Gewehr DM, Teixeira L, Clemente MRC, Reis PCA, de Amorim LGCR, Marinho AD, Mendes TB, Mesquita FC, Pozzi E, Ramasamy R (2025) Long-Term Cardiovascular Safety of Testosterone-Replacement Therapy in Middle-Aged and Older Men: A Meta-analysis of Randomized Controlled Trials. American journal of cardiovascular drugs: drugs, devices, and other interventions. 25(6):767\u2013777. https:\/\/doi.org\/10.1007\/s40256-025-00737-w","DOI":"10.1007\/s40256-025-00737-w"},{"issue":"2","key":"2945_CR61","doi-asserted-by":"publisher","first-page":"229","DOI":"10.1093\/sxmrev\/qeaf013","volume":"13","author":"J Fink","year":"2025","unstructured":"Fink J, Bentzen K, Horie S (2025) Management of hematocrit levels for testosterone replacement patients, a narrative review. Sex Med Rev 13(2):229\u2013236. https:\/\/doi.org\/10.1093\/sxmrev\/qeaf013","journal-title":"Sex Med Rev"},{"issue":"6","key":"2945_CR62","doi-asserted-by":"publisher","first-page":"725","DOI":"10.1093\/gerona\/glt154","volume":"69","author":"E Bachman","year":"2014","unstructured":"Bachman E, Travison TG, Basaria S, Davda MN, Guo W, Li M, Connor Westfall J, Bae H, Gordeuk V, Bhasin S (2014) Testosterone induces erythrocytosis via increased erythropoietin and suppressed hepcidin: evidence for a new erythropoietin\/hemoglobin set point. J Gerontol Biol Sci Med Sci 69(6):725\u2013735. https:\/\/doi.org\/10.1093\/gerona\/glt154 Epub 2013 Oct 24. PMID: 24158761; PMCID: PMC4022090","journal-title":"J Gerontol Biol Sci Med Sci"},{"issue":"1","key":"2945_CR63","doi-asserted-by":"publisher","first-page":"11","DOI":"10.1111\/cen.13723","volume":"89","author":"M Grossmann","year":"2018","unstructured":"Grossmann M (2018) Hypogonadism and male obesity: Focus on unresolved questions. Clin Endocrinol 89(1):11\u201321. https:\/\/doi.org\/10.1111\/cen.13723","journal-title":"Clin Endocrinol"},{"issue":"6","key":"2945_CR64","doi-asserted-by":"publisher","first-page":"2560","DOI":"10.1210\/jc.2009-2575","volume":"95","author":"MM Fern\u00e1ndez-Balsells","year":"2010","unstructured":"Fern\u00e1ndez-Balsells MM, Murad MH, Lane M, Lampropulos JF, Albuquerque F, Mullan RJ, Agrwal N, Elamin MB, Gallegos-Orozco JF, Wang AT, Erwin PJ, Bhasin S, Montori VM (2010) Clinical review 1: Adverse effects of testosterone therapy in adult men: a systematic review and meta-analysis. J Clin Endocrinol Metab 95(6):2560\u20132575. https:\/\/doi.org\/10.1210\/jc.2009-2575","journal-title":"J Clin Endocrinol Metab"}],"container-title":["Journal of Endocrinological Investigation"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40618-026-02945-w.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s40618-026-02945-w","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40618-026-02945-w.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,10,30]],"date-time":"2026-10-30T22:01:00Z","timestamp":1793397660000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s40618-026-02945-w"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,6,27]]},"references-count":64,"journal-issue":{"issue":"11","published-online":{"date-parts":[[2026,11]]}},"alternative-id":["2945"],"URL":"https:\/\/doi.org\/10.1007\/s40618-026-02945-w","relation":{},"ISSN":["1720-8386"],"issn-type":[{"value":"1720-8386","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,6,27]]},"assertion":[{"value":"10 October 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"8 June 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"27 June 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The authors declare no conflict of interest relevant to this manuscript.","order":1,"name":"Ethics","label":"Conflict of interest","group":{"name":"EthicsHeading","label":"Declarations"}}]}}